(Q35728607)

9 August 2017

1 reference

title

T-cell-based immunotherapy of melanoma: what have we learned and how can we improve? (English)

1 reference

9 August 2017

1 reference

2

Soldano Ferrone

1 reference

9 August 2017

Michael Campoli

1

1 reference

9 August 2017

publication date

1 April 2004

1 reference

Expert Review of Vaccines

9 August 2017

published in

1 reference

9 August 2017

volume

3

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

171-187

1 reference

Radiation therapy of malignant melanoma

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Apoptosis and melanoma chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Identification of tumour-associated T-cell epitopes for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Current developments in cancer vaccines and cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Monoclonal antibodies as therapeutics in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

T-cell recognition of melanoma-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Towards patient-specific tumor antigen selection for vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

New paths in human cancer serology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

The makings of a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Cross-presentation, dendritic cells, tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

The cell biology of antigen presentation in dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Immunotherapeutic potential of whole tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

T cell priming versus T cell tolerance induced by synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Exposing the immunology of naked DNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Some quantitative aspects of T-cell repertoire selection: the requirement for regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Analysis of successful immune responses in persons infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

Angiogenesis, lymphangiogenesis, and melanoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.171

21 January 2018

Identifiers

DOI

10.1586/14760584.3.2.171

1 reference

9 August 2017

1 reference